1
Return

Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts

delete2026-06-29
delete0
delete
OA
AI
M
Matthew Spinelli *
M
Megan J Heise *
D
David V Glidden
J
Janet Grochowski
J
Jon Oskarsson
L
Larisa Niles-Carnes
E
Eudiah Ochieng
M
Meredith Lora
A
Amalia Aldredge
N
Nathanael Gistand
C
Chesa Cox
J
Jonathan A Colasanti
M
Monica Gandhi
L
Lauren F Collins
DOI：10.1093/cid/ciag392delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Long-acting cabotegravir/rilpivirine supports virologic suppression among people with HIV (PWH) facing adherence challenges. In two large U.S. cohorts(n=1,070), 96% of viremic PWH achieved virologic suppression at a 4-week median. However, blips/failure were more frequent among PWH initiating with viremia, underscoring the need for careful monitoring and optimization of long-acting treatment.

Journal

Clinical Infectious Diseases cover
Clinical Infectious Diseases
IF:
7.3
Papers:
2.6W
Citations:
7.8W

Organization

U
university of california san francisco
Scholars:
5.2W
Papers: 4.0W
Citations: 66
G
Grady Memorial Hospital
Scholars:
17
Papers: 12
Citations: 1.2K
Cited Papers

Cited Papers

Citing Papers

Citing Papers